logo

Has evidence of a rare side effect from AstraZeneca’s COVID-19 vaccine led European countries to curtail its use?

Tuesday, April 13, 2021
By Gus Fisher
YES

Firmer evidence of a rare side effect from AstraZeneca’s COVID-19 vaccine has led health authorities in Europe to limit its use among younger people.

In the U.K., 79 people developed a rare clotting disorder, and 19 of them died. On April 7, the government advised that people under 30 be offered “an alternative COVID-19 vaccine, if available.” Other European countries have set minimum ages of 55, 60 or 65 for receiving the vaccine.

According to an analysis by GAVI, a global vaccine alliance, about one person in a million has a chance of experiencing the side effect. Researchers say the protection afforded against COVID-19 from the AstraZeneca vaccine, which is less expensive and easier to store and transport than vaccines from Pfizer and Moderna, is likely to offset the side effect risks for much of the world.

The vaccine hasn't been authorized for use in the U.S.

This fact brief is responsive to conversations such as this one.
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
FACT BRIEF BY
facebook
twitter
email
email